Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1

Metastatic colorectal cancer (mCRC) patients have poor overall survival despite using irinotecan- or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, especially those with the oncogene mutation of KRAS. Metformin has been reported as a potentially nove...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jinye, Xia, Liangping, Xiang, Wei, He, Wenzhuo, Yin, Haofan, Wang, Fang, Gao, Tianxiao, Qi, Weiwei, Yang, Zhonghan, Yang, Xia, Zhou, Ti, Gao, Guoquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293710/
https://www.ncbi.nlm.nih.gov/pubmed/32444490
http://dx.doi.org/10.1073/pnas.1918845117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293710/
https://www.ncbi.nlm.nih.gov/pubmed/32444490
http://dx.doi.org/10.1073/pnas.1918845117

Ejemplares similares